Tianjin export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
The archive
Page 164 of 170 of this archive, newest first.
Independent analysis puts a SSA semaglutide lot at 98.0%, against 94.0% on the certificate
The supplier has not disputed the finding. It has not explained the gap either.
A guide to the results that will resolve themselves
Three different explanations for the same abnormal number, and how to tell them apart.
Side effects, cost, supply, target: four reasons with four trajectories
Real-world persistence figures, with their definitions stated, because the definitions are doing most of the work.
Inspectors cite Halvard & Pike Apothecary of Portland, Maine over sterility assurance
The observation that closes a facility is rarely the dramatic one.
The 6-day notice: how a compounding wind-down works in Germany
The document is four pages. Three of them are about dates.
What changed at SSA in February, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
PeptideMeter result on a Qingdao cagrilintide lot lands 2.2 points below the supplier’s figure
A reminder that a purity figure is the output of a method, and that methods differ.
What SURPASS-3 tells us about maintenance, and what it does not
What the labels permit, what clinicians do, and the size of the gap between them.
Bone density during rapid weight loss: what is known, which is less than you would hope
Weight loss reduces bone mineral density at load-bearing sites. Whether that translates into fractures in this population is unmeasured.
Set the threshold at a tenth of a per cent and the small impurities vanish
We work through a single chromatogram twice, under two integration conventions, and show where the difference comes from.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
What changed at KP in February, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Nigeria pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
The relabeller trading as Vantris Bio enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
Adsorption, and the dose that stayed on the glass
Every degradation pathway accelerates by orders of magnitude on reconstitution, because the solvent that lyophilisation removed is the reagent most of them need.
Norway health authority warns on falsified semaglutide pens
Reported from the analysis, not from a warning notice.
SURMOUNT-OSA misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
What the new India guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Calder Vale Peptides of Skipton closes after 3 years
A proper account of an operation that existed, and of what closing it cost.
The arithmetic of a step: what doubling a dose actually asks of you
What the published pharmacokinetics permit, what the labels state, and where the two diverge.
Background rates, and why they matter for attribution
Rapid weight loss by any means raises gallstone risk. Separating that from a direct drug effect requires a comparator, and the trials have one.
The escalation table is the thinnest page in the label
The published ladder exists because a protocol needed a single number. Practice has never followed it exactly, and the regulatory file never assumed it would.
SURMOUNT-4 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Independent analysis puts a MKM survodutide lot at 97.0%, against 95.7% on the certificate
The result is unremarkable. What the report omits is not.
A shortage listing ends. 7 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The consolidator trading as Meridian Freight Partners enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
Who chose the vial that was tested?
The condition on arrival is recorded by some services and not others, and it is one of the more informative lines in a report.
The cold chain in this trade is a gel pack and an optimistic estimate
A gel pack has a finite thermal budget, and once it is spent the payload equilibrates with whatever is outside the box. The only question is how long that takes.
What a 7% rise in coupling-reagent prices does to a 5 mg vial
Follow the resin, not the catalogue.